Loading company…
Spyryx Biosciences develops inhaled therapeutics for obstructive lung diseases such as cystic fibrosis and COPD.
Founded in 2013 and based in Durham, US, Spyryx Biosciences develops therapies for obstructive lung diseases. Its lead investigational product, SPX-101, is an inhaled peptide that targets epithelial sodium channels to improve mucociliary clearance, and it is in Phase 2 trials in Canada, the UK, France, and Portugal for adults with cystic fibrosis. In October 2018 the company raised USD 5.93 mn in a Venture Debt round, bringing total funding to USD 18.17 mn across 4 deals. Its listed stage is Series A.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in